Annotation Detail
Information
- Associated Genes
- CDK6
- Associated Variants
-
CDK6 OVEREXPRESSION
(
ENST00000265734.8 )
CDK6 OVEREXPRESSION ( ENST00000265734.8 ) - Associated Disease
- estrogen-receptor positive breast cancer
- Source Database
- CIViC Evidence
- Description
- In two cohorts (n=45 and n=46) of ER+ breast cancer patients who had received fulvestrant, CDK6 overexpression correlated with shorter median time to progression in both cohorts (2.5 vs. 8.2 months and 3.4 vs. 8.9 months for CDK6 overexpression vs. normal expression). CDK6 expression did not correlate with other lines of treatment (N=68, tamoxifen or endocrine therapy). Four fulvestrant-resistant cell lines were derived from estrogen responsive and fulvestrant sensitive parental breast cancer cell line MCF-7/SO.5. Gene expression profiling showed upregulation of CDK6 in the fulvestrant resistant derivatives. Knockdown of CDK6 in these derivative cells resulted in fulvestrant sensitivity.
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1526
- Gene URL
- https://civic.genome.wustl.edu/links/genes/12
- Variant URL
- https://civic.genome.wustl.edu/links/variants/602
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Estrogen-receptor Positive Breast Cancer
- Evidence Direction
- Supports
- Drug
- Fulvestrant
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 27252418
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Fulvestrant | Resitance or Non-Reponse | true |